GRM5 and fragile X syndrome: Other potential treatments to be assayed in FXS have been first tested for synaptic plasticity normalization, such as the agonist for serotonin 5-HT7 receptors [40], on the bases that enhanced mGluR5-LTD is a synaptic plasticity landmark in FXS.